Breast Cancer Therapeutics Market Scope And Analysis

Report Code : TIPRE00030059
Category : Pharmaceuticals

Status : Published
No. of Pages : 204

Buy Now

Breast Cancer Therapeutics Market Analysis and Scope (2023 to 2030)

Buy Now

Breast Cancer Therapeutics Market Report Scope

Report Attribute	Details
Market size in 2022	US$ 31.07 Billion
Market Size by 2030	US$ 63.97 Billion
Global CAGR (2022 - 2030)	9.4%
Historical Data	2020-2021
Forecast period	2023-2030
Segments Covered	By Drug Therapy Targeted Drug Therapy Hormonal Drug Therapy Chemotherapy Immunotherapy/Biological Therapy By Breast Cancer Type Hormone Receptor HER2+ Triple-Negative Breast Cancer By Distribution Channel Hospital Pharmacies Drug Stores and Retail Pharmacies Online Pharmacies
Regions and Countries Covered	North America US Canada Mexico Europe UK Germany France Russia Italy Rest of Europe Asia-Pacific China India Japan Australia Rest of Asia-Pacific South and Central America Brazil Argentina Rest of South and Central America Middle East and Africa South Africa Saudi Arabia UAE Rest of Middle East and Africa
Market leaders and key company profiles	Eli Lilly and Co Eisai Co Ltd Novartis AG AstraZeneca Plc Pfizer Inc Gilead Sciences Inc Merck Co Inc Genentech Inc Teva Pharmaceutical Industries Ltd

Industry Developments and Future Opportunities:

Various initiatives taken by key players operating in the global breast cancer therapeutics market are listed below:

In February 2023, Gilead Sciences, Inc. received US Food and Drug Administration (FDA) approval Trodelvy (sacituzumab govitecan-hziy) for the treatment of adult patients with unresectable locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer who have received endocrine-based therapy and at least two additional systemic therapies in the metastatic setting..
In November 2022, Eli Lilly and Company launched the additional indication for Ramiven (abemaciclib), following approval from the Drugs Controller General of India (DCGI), in combination with endocrine therapy for adjuvant treatment in adult patients with Hormone Receptor (HR)-positive, HER2 negative, node-positive EBC at high risk of recurrence.
In January 2020, Eisai Co., Ltd launched the in-house developed anticancer agent Halaven in China. In China, Halaven received new drug approval for its use in treating patients with locally advanced or metastatic breast cancer, previously treated with at least two prior chemotherapy regimens.

Competitive Landscape and Key Companies:

Eli Lilly and Co, Eisai Co Ltd, Novartis AG, AstraZeneca Plc, Pfizer Inc, Gilead Sciences Inc, Merck & Co Inc, Genentech Inc, Teva Pharmaceutical Industries Ltd, and Amgen Inc are among the major breast cancer therapeutics companies. These companies focus on new technologies, advancements in existing products, and geographic expansions to meet the growing consumer demand worldwide.